Company / Depreciation & Amortization
ADMA Biologics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$8.0M
FY2025
5-year range
$4.8M / $8.0M
FY2021-FY2025
Trend
+3.9%
vs FY2024
Sector context
#71 of 163
Health Care
What the data says
At $8M, ADMA Biologics, Inc.'s depreciation & amortization ranks #93 of 163 in the Health Care sector. Depreciation & Amortization has increased for 3 consecutive years, from $5M in FY2022 to $8M in FY2025.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +20.1%.
Increased from $8M to $8M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +18.6%
- 5-Year CAGR
- +20.1%
- 10-Year CAGR
- -
Sector benchmark
#93 of 163 in Health CareTop 56% of 163This company $8.0M Sector average $219.4M
▼
-96.4% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +20.1%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 3.9% year-over-year.
- Ranks #71 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.0M | +3.9% |
| FY2024 | $7.7M | +1.3% |
| FY2023 | $7.6M | +58.3% |
| FY2022 | $4.8M | +0.0% |
| FY2021 | $4.8M | +50.0% |
| FY2020 | $3.2M | +33.3% |
| FY2019 | $2.4M | -7.7% |
| FY2018 | $2.6M | +550.0% |
| FY2017 | $400.0K | +0.0% |
| FY2016 | $400.0K | +61.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026